None listed
Conditions
Interventions
Others : images for 60 minutes after Ga-68 PSMA-11 injection
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patients who are older than19 years and capable of providing signatures in consent forms - Patients diagnosed with or suspected primary hepatocellular carcinoma by clinical information (blood test AFP, PIVKA elevation, etc.), imaging or pathology. - Patients with BCLC stage B or higher grade - Patients who have performed or are scheduled to perform tri-phase abdominal pelvic CT within a four-week period before Ga-68 PSMA-11 PET/CT and a two-week period after Ga-68 PSMA PET/CT after study enrollment - Patients who are willing to make a follow-up observation in our hospital for at least 6 months after study enrollment
Exclusion criteria
Exclusion criteria: - If other primary cancers other than liver cancer were previously diagnosed or occurred at the same time - Patients within 3 weeks after chemotherapy or within 4 weeks after hepatic artery chemoembolization - Patients are under severe and/or uncontrolled and/or unstable medical conditions (e.g., congestive heart failure, acute myocardial infarction, degenerative brain disease, severe lung disease, etc.) - Patients who cannot stably perform CT or PET/CT imaging tests due to claustrophobia, dyskinesia, anxiety disorders, and etc - Where it is determined that the patient will not be eligible to completely collect data for clinical trials due to personal circumstances or other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection sensitivity and positive predictive value of Ga-68 PSMA-11 PET/CT | — |
Secondary
| Measure | Time frame |
|---|---|
| Additional diagnostic value of Ga-68 PSMA-11 PET/CT to conventional CT ;Comparison of staging (BCLC) before and after adding Ga-68 PSMA-11 PET/CT | — |
Countries
Korea, Republic of
Contacts
Public ContactJae Eun Kim
Asan Medical Center
Outcome results
None listed